Pfizer Recalls RELPAX® Tablets

2019-08-15 |

Pfizer Inc. has voluntarily recalled RELPAX® 40 mg tablets due to potential contamination with Pseudomonas and Burkholderia. RELPAX® is indicated for treatment of migraine. The affected lots were distributed to wholesalers, retailers, hospitals, and healthcare providers from June to July 2019. Read the FDA alert.